Cold hypersensitivity and oxidative stress are prominent features of chemotherapy-induced neuropathies, for which there is no US Food and Drug Administration-approved treatment.80 Thus, we hypothesized that DJ-1 might play a significant role in these neuropathies and could serve as a therapeutic target. This evidence concerns the gene PARK7 and neuropathy.